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ABSTRACT
Introduction: While incretin-based therapies
have been compared in clinical trials, data
comparing their relative efficacy in clinical
practice remain limited, particularly when
prescribed according to clinical guidelines.
This study assessed the clinical and cost-
effectiveness of, and patient preference for,
incretin-based therapies initiated according to
the National Institute for Health and Clinical
Excellence (NICE) recommendations in UK
clinical practice.
Methods: In a retrospective chart audit,
anonymized data were collected for patients
receiving incretin-based therapy according to
NICE recommendations in clinical practice in
Wales, UK. Parameters assessed included glycated
hemoglobin (HbA1c), weight, achievement of
NICE treatment continuation criteria, adverse
events, treatment discontinuation, and drug
cost-effectiveness based on observed treatment
effects. Treatment preference for a dipeptidyl
peptidase-4 inhibitor (DPP-4i) or glucagon-like
peptide-1 receptor agonist (GLP-1RA) was
assessed prospectively.
Results: Patients (1,114) were followed-up for a
median of 48 weeks (256 received liraglutide,
148 received exenatide twice daily, and 710
received a DPP-4i). Liraglutide reduced HbA1c
significantly more versus exenatide or DPP-4i
(both P\0.05). Weight changes were similar for
GLP-1RAs but significantly greater vs. DPP-4is
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(both P\0.05). NICE treatment continuation
criteria were met by 32% and 24% of liraglutide
1.2 mg- and exenatide-treated patients (C1%
HbA1c reduction, C3% weight loss), and 61%
of DPP-4i-treated patients (C0.5% HbA1c
reduction). Life-years gained per patient were
0.12, 0.08, and 0.07, and costs per quality-
adjusted life-year were £16,505, £16,648, and
£20,661 for liraglutide, exenatide, and DPP-4is,
respectively. More patients (62.5%) preferred
the GLP-1RA profile, with these patients having
higher baseline body mass index score and
HbA1c values, and longer diabetes duration
than those preferring the DPP-4i profile.
Conclusion: When prescribed according to NICE
recommendations, incretin-based therapies are
both clinically and cost-effective options, with
liraglutide providing greatest HbA1c reductions.
Greater body weight reductions occur with GLP-
1RAs compared with DPP-4is. Patients with
higher baseline HbA1c and longer diabetes
duration prefer a GLP-1RA profile versus a DPP-4i.
Keywords: Clinical effectiveness; Cost-
effectiveness; Incretin therapies; Routine
clinical practice; Type 2 diabetes
INTRODUCTION
When metformin and lifestyle changes become
insufficient in treating type 2 diabetes
mellitus (T2DM), advancing treatment with
traditional therapies (sulfonylureas [SUs],
thiazolidinediones [TZDs], and insulin) can be
complicated by weight gain and hypoglycemia
[1]. In clinical trials, adding incretin-based
therapies to existing oral therapy has been
shown to improve glycemic control without
weight gain and with low hypoglycemia
incidence (especially when used without SUs)
[2–6]. Head-to-head studies of up to 12 months’
duration suggest that glucagon-like peptide-1
receptor agonists (GLP-1RAs) have greater
glycemic efficacy and result in significantly
more weight loss compared with the
dipeptidyl peptidase-4 inhibitor (DPP-4i)
sitagliptin [7–10]. Furthermore, patient-
reported data suggest a greater improvement
in treatment satisfaction with liraglutide 1.8 mg
versus sitagliptin; treatment satisfaction data
were similar for liraglutide 1.2 mg versus
sitagliptin [11].
The National Institute of Health and Clinical
Excellence (NICE) recommendations for
incretin-based therapies reflect their key
benefits, endorsing use (in combination with
one or two oral therapies) when hypoglycemia
and/or weight gain are a particular concern
[12–14]. In general, DPP-4is recommended
earlier in the treatment pathway, with less
stringent treatment continuation criteria
compared with GLP-1RAs. While incretin-
based therapies have been compared in
clinical trials [7–10, 15, 16], Data comparing
their relative efficacy in clinical practice
remains limited, particularly when prescribed
according to clinical guidelines.
With these issues in mind, using primary
care data, a retrospective chart audit was
conducted to compare the clinical and cost-
effectiveness of liraglutide, exenatide twice
daily (b.i.d.), and DPP-4is when initiated
according to current NICE recommendations.
Once-weekly exenatide was not included as it
was unavailable for routine use at the time of
this study. As NICE also advocates patient
involvement in therapy choice and treatment
goals [17], the audit was complemented by a
prospective patient preference survey in
patients considered appropriate for treatment
intensification with incretin-based therapy. The
survey’s aim was to compare preferences for
GLP-1RAs with DPP-4is. Based on clinical trial
28 Diabetes Ther (2013) 4:27–40
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data, it was hypothesized that liraglutide would
provide greater glycated hemoglobin (HbA1c)
efficacy compared with DPP-4is and exenatide.
As GLP-1RA use can result in weight loss, we
also hypothesized that patients with a greater
baseline body mass index (BMI) would prefer a
drug with a GLP-1RA profile.
PATIENTS AND METHODS
Retrospective Survey, Patient Selection,
Data Collection, and Analyses
Anonymized data were collected from 15
participating primary care centers in South
Wales, UK, for patients with T2DM commencing
treatment with a DPP-4i or GLP-1RA between May
2009 and November 2011 in accordance with
current NICE recommendations [12, 13]. Data
were collected at baseline and 3, 6, 9, and
12 months after incretin-based therapy
initiation, and at audit end (November 2011).
Extracted outcome data comprised HbA1c,
weight, blood pressure, total cholesterol, and
plasma triglycerides. Data on treatment
discontinuation (including reasons for
switching) and adverse events (AEs; including
symptomatic hypoglycemia or severe
hypoglycemia [requiring third-party assistance])
were also collected, where available.
Endpoints were calculated for the intent-to-
treat population (patients receiving at least one
dose of incretin-based therapy). Based on
similar efficacy results for DPP-4is in clinical
trials [18], patients receiving sitagliptin,
saxagliptin, or vildagliptin were pooled into a
DPP-4i treatment group. GLP-1RA use was
divided into two groups—liraglutide (1.2 mg
and 1.8 mg) and exenatide BID—due to
significant differences in glycemic efficacy
reported in a head-to-head clinical trial [15].
For baseline demographics, differences in the
mean of continuous and categorical variables
were compared using repeated analysis of
variance (ANOVA). Changes from baseline to
each time point were calculated for each group
for HbA1c, weight, blood pressure, total
cholesterol, and plasma triglyceride at 3, 6, 9,
and 12 months, after checking residuals for
normality. For patients previously receiving a
DPP-4i, changes in HbA1c and weight from
baseline were assessed following 12 months of
liraglutide or exenatide treatment. Similarly, for
patients previously receiving exenatide, the
effect of 12-months liraglutide treatment was
evaluated. No patients switched from liraglutide
to exenatide.
The proportion of patients satisfying the
NICE 6-month treatment continuation criteria
[12, 13] for DPP-4is (C0.5% HbA1c reduction)
and triple-therapy GLP-1RA use (C1% HbA1c
reduction with C3% weight loss) was assessed.
When used as dual therapy, liraglutide has
different continuation criteria (C1% HbA1c
reduction) but, due to the small numbers of
patients receiving this combination in this
audit, for the endpoint analysis, the more
stringent triple-therapy continuation criteria
were applied. The proportion of patients
achieving the composite endpoint C1% HbA1c
reduction coupled with any weight loss was also
analyzed. Comparisons between treatment
groups were performed for the proportion of
patients achieving the composite endpoint,
frequency of treatment discontinuation, AEs,
and hypoglycemia. Summary statistics were
calculated for AEs and discontinuation, and
changes in other blood glucose-lowering
therapies.
All analyses were performed using SAS
version 9.1 (SAS Institute Inc., Cary, NC, US).
P-values\0.05 were deemed statistically
significant. Statistical calculations were
Diabetes Ther (2013) 4:27–40 29
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performed using Minitab release 14.11
(Minitab Ltd, Coventry, UK).
Cost-Effectiveness
Based on observed treatment effects versus
baseline, the UK Prospective Diabetes Study
(UKPDS) 68 risk equations [19] were applied
over a 20-year time horizon into the CORE
diabetes model to independently calculate the
cost-effectiveness of liraglutide, exenatide, and
DPP-4is. This time horizon was chosen based on
the mean patient age at therapy initiation and
was thus considered to represent lifetime
exposure. Cost per quality-adjusted life-year
(QALY) for patients prescribed a DPP-4i was
based on the annualized retail acquisition cost
of the most commonly prescribed agent,
sitagliptin (£433.57 per year) [20]. In addition,
due to the different annual acquisition costs for
the two liraglutide doses, cost calculations were
based solely on patients receiving the 1.2 mg
dose (£954.84 per year) [20] as the vast majority
of patients were prescribed this dose. Standard
acquisition costs were used for exenatide b.i.d.
(£830.25 per year) [20].
Prospective Survey of Patient Preference
From August 4, 2011 to November 8, 2011,
treatment preference was assessed in a separate
group of patients judged by their primary
care practitioner (PCP) to require therapy
intensification and for whom incretin-based
therapy was appropriate according to NICE
recommendations. Patients were shown two
medication ‘‘profiles’’ by their PCP: one
representing a DPP-4i (sitagliptin), the other a
GLP-1RA (liraglutide) (Table 1). As the longest
head-to-head study was between sitagliptin and
liraglutide, data from that study were used for
the patient preference questionnaire for route of
administration, efficacy, side effects, and
treatment satisfaction [7, 8, 11]. Informed
consent was obtained and patients were asked
which drug they would prefer to be prescribed in
addition to their current medication if their
blood sugar levels were too high. Subsequent
responses were anonymized and results collated.
As in a previous patient preference survey [21],
after patients reported their preference, they
were asked to rank the importance of the
following reasons for their decision:
administration method (oral or injection); blood
glucose-lowering effect; side-effects (nausea,
vomiting, and diarrhea); and other effects
(weight loss and blood pressure decrease).
Continuous variables were compared using a
t test, categorical variables using a v2 test, and
overall patient preference was assessed by logistic
regression, controlling for all demographic and
patient characteristic variables. All analyses and
statistical calculations were performed using SAS




In total, 1,114 patients had detailed baseline
and follow-up data and were included in the
retrospective audit: 256 received liraglutide
(1.2 mg once daily (o.d.): 229; 1.8 mg o.d.: 27),
148 exenatide 10 lg b.i.d., and 710 a DPP-4i
(sitagliptin 100 mg o.d., n = 425; vildagliptin
50 mg o.d. or b.i.d., n = 210; saxagliptin 5 mg
o.d., n = 75). The median (range) follow-up for
the audit group as a whole was 48 (0.4–119)
weeks.
At baseline, patients initiated on liraglutide
or exenatide therapy had significantly higher
mean baseline HbA1c, durations of diabetes, and
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mean body weights compared with patients
starting DPP-4is (Table 2). Furthermore, the
majority (92%) of GLP-1RA use was in triple
therapy, while over 15% of DPP-4i use was in
dual combination with metformin. Additionally,
a significantly greater proportion of patients








Caucasian (%) 92.1 93.6 89.4 NS
Male (%) 66.9 59.3 53.8 NS
Age, years (±SD) 63.5 (8.9) 64.1 (9.5) 59.5 (7.8) NS
HbA1c (mmol/mol) 81 84 65 \0.05*
,**
HbA1c [% (±SD)] 9.6 (0.5) 9.8 (0.8) 8.1 (0.4)
Recorded duration of diabetes [years (±SD)] 11.5 (6.6) 12.8 (8.2) 6.9 (4.1) \0.05*,**
Weight [kg (±SD)] 109.7 (9.9) 110.6 (10.7) 88.9 (9.1) \0.05*,**
BMI [kg/m2 (±SD)] 39.5 (6.4) 40.2 (8.6) 31.1 (4.5) \0.05*,**
Blood pressure [mmHg (±SD)] 156/86 (11/6) 160/88 (15/8) 153/79 (10/6) NS
Total cholesterol [mmol/L (±SD)] 4.5 (0.4) 4.1 (0.6) 4.6 (0.7) NS
Plasma triglycerides [mmol/L (±SD)] 2.9 (1.4) 2.8 (1.9) 2.6 (1.8) NS
Previous oral therapy
Metformin monotherapy (%) 5.5 2.7 15.8 \0.05*,**
Metformin/SU combination therapy (%) 79.5 78.9 60.1 \0.05*,**
Metformin and TZD combination
therapy (%)
12.2 13.5 16.9 NS
SU monotherapy (%) 3.2 3.9 4.1 NS
TZD monotherapy (%) 2.6 3.7 3.1 NS
Previous incretin-based therapy
DPP-4i (%) 21.1 6.8 N/A \0.05***
Exenatide (%) 23.5 N/A N/A NC
Lipid-lowering therapy (%) 91.6 93.4 91.9 NS
Antihypertensive therapy (%) 88.9 86.9 85.7 NS
Data are expressed as mean (SD), unless otherwise stated
No patients had previously been treated with liraglutide
* P\0.05 liraglutide versus DPP-4i, ** P\0.05 exenatide versus DPP-4i, *** P\0.05 liraglutide versus exenatide
BMI body mass index, DPP-4i dipeptidyl peptidase-4 inhibitor, GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c
glycated hemoglobin, N/A not applicable, NS not signiﬁcant, NC not calculated, SD standard deviation, SU sulfonylurea,
TZD thiazolidinedione
32 Diabetes Ther (2013) 4:27–40
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starting with liraglutide were receiving a DPP-4i
at baseline, compared with those starting with
exenatide (21.1 vs. 6.8%; P\0.05); DPP-4i
therapy was discontinued in 97% and 98% of
patients starting liraglutide and exenatide,
respectively.
Efficacy
Significant reductions in HbA1c from baseline to
audit end were apparent in all three treatment
groups (all P\0.05) (Fig. 1). The change in
mean HbA1c was significantly greater for
liraglutide (1.2 and 1.8 mg) than exenatide or
DPP-4is (both P\0.05), but not for exenatide
versus DPP-4i (Fig. 1). Significant reductions in
weight from baseline to audit end were
observed for patients receiving a GLP-1RA
(Fig. 2), with 3.1 and 2.1 kg greater weight
reduction seen for liraglutide- and exenatide-
treated subjects, respectively, versus those
prescribed a DPP-4i. Mean HbA1c or weight at
12 months was not statistically different to the
3-, 6-, and 9-month measurements for each
group (Table 3). Considering only those
receiving liraglutide 1.8 mg (n = 27), the mean
(standard deviation [SD]) HbA1c and body
weight reductions from baseline were 1.28%
(±0.35) and 4.1 kg (±7.2), respectively. Twelve
liraglutide-treated subjects, 32 exenatide-
treated subjects, and 25 DPP-4i-treated subjects
either failed to complete 3 months of therapy or
had no available follow-up data; tolerability
issues were the most commonly recorded reason
for therapy discontinuation over this time
frame (n = 9 [liraglutide]; n = 27 [exenatide],
and n = 9 [DPP-4i]).
Patients previously treated with a DPP-4i
switched to GLP-1RA following inadequate
glucose reduction. In these patients,
reductions in HbA1c and weight from baseline
were apparent following 12-month liraglutide
Fig. 1 Mean (SD) reduction in glycated hemoglobin
(HbA1c) from baseline to end of audit. *P\0.05 versus
baseline. DPP-4i dipeptidyl peptidase-4 inhibitor, SD
standard deviation
Fig. 2 Mean (SD) reduction in weight from baseline to
end of audit. *P\0.05 versus baseline. DPP-4i dipeptidyl
peptidase-4 inhibitor, SD standard deviation
Diabetes Ther (2013) 4:27–40 33
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(1.2 mg or 1.8 mg) (n = 54) (-0.9 ± 0.6%
and -2.5 ± 1.8 kg) or exenatide (n = 12)
(-0.7% ± 0.9% and -2.3 kg ± 2.1 kg) treatment;
the changes were statistically significant with
liraglutide (both P\0.05 vs. baseline) but not
exenatide. For previous exenatide-treated
patients, the most common reasons for
conversion to liraglutide therapy were
tolerability problems (62.6%) and insufficient
HbA1c reduction (28.4%), with a mean (±SD)
exposure to exenatide of 8.7 (±6.6) weeks.
Following 12-month liraglutide treatment,
significant HbA1c (-0.8% ± 0.3%) and weight
(-2.1 kg ± 3.1 kg) reductions were observed
(both P\0.05).
The proportions of patients achieving the
NICE 6-month treatment continuation criteria
for GLP-1RAs with liraglutide 1.2 mg and
exenatide were 32% and 24%, respectively.
For DPP-4is, 61% of patients achieved the less
stringent criteria at 6 months. The composite
endpoint of C1% HbA1c reduction with any
weight loss was achieved by 60%, 48%,
and 14% of patients treated with liraglutide
Table 3 Change from baseline in recorded parameters at 3, 6, 9, and 12 months, and at the end of audit
Liraglutide (1.2 or 1.8 mg) Time since initiation of incretin treatment (months)
3 6 9 12 Audit enda
n 5 244 n 5 238 n 5 209 n 5 181 n 5 129
HbA1c [% (±SD)] -1.29 (0.2)*
,** -1.21 (0.2)*,** -1.19 (0.1)*,** -1.15 (0.1)*,** -1.22 (0.1)*,**
Body weight [kg (±SD)] -4.4 (4.9)** -2.9 (5.7) -3.6 (5.8)** -3.5 (6.1)** -3.3 (5.9)**
Blood pressure [mmHg (±SD)] -2.8/1.1 (5.5/4.2) -2.4/0.9 (4.1/3.5) -2.6/1.1 (4.1/4.2) -2.2/1.1 (3.5/4.7) -1.5/1.9 (5.5/3.9)
Total cholesterol [mmol/L (±SD)] -0.3 (0.5) -0.2 (0.4) ?0.1 (1.5) -0.2 (0.3) ?0.1 (0.3)
Plasma triglycerides [mmol/L (±SD)] -0.4 (0.6) -0.5 (0.8) -0.4 (0.9) -0.2 (0.6) -0.3 (0.8)
% Achieving NICE criteriab 35 32 31 29 28
Exenatide Time since initiation of incretin treatment (months)
3 6 9 12 Audit enda
n 5 116 n 5 101 n 5 96 n 5 92 n 5 66
HbA1c [% (±SD)] -0.8 (0.19) -0.72 (0.15) -0.69 (0.36) -0.75 (0.22) -0.71 (0.31)
Body weight [kg (±SD)] -3.1 (4.8) -2.7 (5.7)*** -2.9 (6.2)*** -3.1 (6.9)*** -2.5 (5.9)***
Blood pressure [mmHg (±SD)] -2.1/1.3 (4.4/2.5) -1.5/2.1 (5.5/5.9) -2.2/2.6 (4.8/3.9) -1.9/1.7 (4.1/4.9) -2.1/1.1 (4.4/3.7)
Total cholesterol, mmol/L (±SD) -0.2 (0.2) ?0.2 (0.4) -0.3 (0.2) -0.1 (0.2) ?0.1 (0.3)
Plasma triglycerides, mmol/L (±SD) -0.6 (0.6) -0.5 (0.4) -0.3 (0.7) -0.3 (0.8) -0.2 (0.8)
% Achieving NICE criteria 27 24 26 25 21
DPP-4i Time since initiation of incretin treatment (months)
3 6 9 12 Audit enda
n 5 685 n 5 551 n 5 471 n 5 301 n 5 266
HbA1c [% (±SD)] -0.79 (0.21) -0.69 (0.15) -0.71 (0.14) -0.74 (0.11) -0.66 (0.19)
Body weight [kg (±SD)] -0.9 (2.1) -0.5 (1.9) -1.1 (0.4) -0.6 (0.9) -0.7 (0.5)
Blood pressure [mmHg (±SD)] ?1.1/0.9 (3.5/2.9) -1.3/1.7 (4.4/3.1) ?0.9/2.1 (5.5/3.7) -1.5/1.1/(5.5/3.9) -1.1/1.9 (4.5/3.9)
Total cholesterol [mmol/L (±SD)] -0.1 (0.4) -0.1 (0.5) -0.3 (0.4) -0.1 (0.6) -0.2 (0.4)
Plasma triglycerides [mmol/L (±SD)] -0.2 (0.2) -0.4 (0.9) -0.2 (0.4) -0.3 (0.4) -0.3 (0.3)
% Achieving NICE criteria 59 61 52 54 57
Data are expressed as mean (±SD), unless otherwise stated
NICE continuation criteria for GLP-1RA therapy: C1% reduction in HbA1c and C3% body weight loss
NICE continuation criteria for DPP-4i therapy: C0.5% reduction in HbA1c
DPP-4i dipeptidyl peptidase-4 inhibitor, GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin, NICE National Institute for Health and Clinical
Excellence, SD standard deviation
* P\ 0.05 liraglutide versus exenatide; ** P\ 0.05 liraglutide versus DPP-4i; *** P\ 0.05 exenatide versus DPP-4i
a For patients with 12-month data
b Only for patients receiving liraglutide 1.2 mg
34 Diabetes Ther (2013) 4:27–40
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(1.2 mg and 1.8 mg), exenatide, or a DPP-4i,
respectively.
Treatment Discontinuation and AEs
SU and TZD discontinuation was similar for both
GLP-1RA- and DPP-4i-treated patients (liraglutide
group: 6.9% and 7.9%; exenatide group: 8.6%
and 10.9%; DPP-4i group; 7.2% and 12.1%).
Insufficient HbA1c reduction was the most
frequent reason for DPP-4i discontinuation
(83%), while tolerability problems (22% and
42%) and insufficient HbA1c-lowering effects
(27% and 29%) were the smost commonly
recorded reasons for liraglutide and exenatide
discontinuation, respectively.
AEs were more common in patients taking
exenatide and liraglutide (39% and 29%,
respectively) than DPP-4is (9.6%). The most
commonly recorded AEs with liraglutide (26.5%)
and exenatide (33.1%) were gastrointestinal
(diarrhea, nausea, vomiting, abdominal pain,
constipation, anorexia). The most commonly
reported side effects with DPP-4is were diarrhea
(3.9%), headache (2.1%), and nausea (1.7%). No
major hypoglycemia was recorded; symptomatic
hypoglycemia was recorded in 0.8%, 0.9%, and
0.8% of people taking liraglutide, exenatide, or a
DPP-4i, respectively.
Cost-Effectiveness Analyses
Based on the end-of-audit observations, the
calculated life-years gained per patient,
compared with baseline, were 0.12, 0.08, and
0.07 for liraglutide, exenatide, and DPP-4i,
respectively. The observed costs per QALY versus
baseline for patients prescribed liraglutide,
exenatide, or DPP-4i were £16,505, £16,648, and
£20,661, respectively.
Prospective Survey of Patient Preference
A total of 188 patients completed the survey,
with a mean (±SD) age of 63.9 years (±5.9),
body weight 97.5 kg (±8.6), BMI 36.7 kg/m2
(±5.9), and HbA1c 74 mmol/mol (8.9%) (±1.1).
Based on medication profiles provided,
significantly more patients (62.5% vs. 37.5%)
reported a preference for the drug with the GLP-
1RA profile compared with the DPP-4i profile
(P\0.05). The demographics of patients
choosing each drug are shown in Table 4.
Weight loss was ranked the most important
determinant of choice by 61% of patients
choosing the GLP-1RA profile, and mode of
administration by 66% of patients choosing the
DPP-4i profile. Logistic regression analysis
demonstrated that the likelihood of preferring
the drug with the GLP-1RA profile grew with
increasing BMI (odds ratio [OR] 1.54; 95%
confidence interval [CI] 1.22–1.69), duration
of diabetes (OR 1.32; 95% CI 1.12–1.99), and
HbA1c level (OR 1.09; 95% CI 1.04–1.29).
DISCUSSION
This retrospective UK case-note survey
examined outcomes of therapy with GLP-1RAs
(reported separately for liraglutide and
exenatide) and DPP-4is (pooled for sitagliptin,
vildagliptin, and saxagliptin) in routine
practice. As treatments were initiated
according to NICE recommendations [12, 13],
patients prescribed GLP-1RAs had longer disease
duration and higher baseline HbA1c and BMIs
compared with patients prescribed DPP-4is. In
this context, liraglutide provided a significantly
greater mean reduction in HbA1c versus DPP-4is
or exenatide; reduction in HbA1c was similar
with exenatide and DPP-4is. Furthermore, in
keeping with current NICE recommendations
Diabetes Ther (2013) 4:27–40 35
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[13], the vast majority of liraglutide use was
with 1.2 mg. Mean weight loss was greater with
liraglutide compared with DPP-4is and
exenatide, and was significantly greater with
either GLP-1RA therapy compared with DPP-4is.
A total of 32% and 24% of patients treated with
liraglutide 1.2 mg and exenatide, respectively,
met the 6-month NICE treatment continuation
criteria for GLP-1RAs, while 61% of patients
treated with a DPP-4i achieved their less
stringent criteria [12, 13]. Based on input of
the observed clinical effects of the different
treatment options as applied of the UKPDS 68
risk equations into the widely accepted CORE
diabetes model, liraglutide, exenatide, and
DPP-4i therapy were cost-effective treatment
options as prescribed at the currently accepted
threshold of acceptability of £20,000 per QALY
[12–14], although no direct comparison of the
cost-effectiveness profile of these agents could
be made from this study since baseline patient
demographics were different, coupled with the
absence of a randomized approach to therapy
initiation. The majority of patients (62.5%)
preferred the GLP-1RA profile, and these
patients had greater BMIs, HbA1c, and
durations of diabetes than patients preferring
the DPP-4i.
While our observed relative efficacies of the
incretin-based therapies are generally supported
by head-to-head clinical trial data comparing
liraglutide, exenatide, and sitagliptin [7, 8, 15],
other factors may contribute to our
observations. Baseline characteristics differed
among treatment groups, with the DPP-4i
group having lower HbA1c and BMIs than the
GLP-1RA groups. Additionally, more patients in
the liraglutide group than the other groups
reduced or discontinued SU therapy, which may
have contributed to greater absolute weight
reduction observed in this cohort.
The relatively poor performance of
liraglutide and exenatide in achieving the
NICE treatment continuation criteria may
reflect their later use in the disease course
(baseline HbA1c 81–84 mmol/mol [9.6–9.8%],
duration of diabetes 11.5–12.8 years) compared
with the phase 3 studies (HbA1c 63–70 mmol/
mol [7.9–8.6%], duration of diabetes 5–10 years)
upon which the criteria are based [2, 22].
Achieving a 6-month 3% body weight loss
may have been unrealistic for severely obese
Table 4 Distribution and clinical proﬁle of respondents









n [% (±SD)] 70 (37.5) 118 (62.5) \0.05
Age [years (±SD)] 59.5 (5.1) 62.6 (6.1) N/A
Male/female (%) 54/46 59/41 NS
Body weight [kg
(±SD)]
88.9 (5.6) 98.5 (6.9) \0.05
BMI [kg/m2
(±SD)]
















Data are expressed as mean (±SD), unless otherwise stated
Comparisons made between people expressing a preference
for drug B (GLP-1RA proﬁle) versus drug A (DPP-4i
proﬁle)
BMI body mass index, DPP-4i dipeptidyl peptidase-4
inhibitor, GLP-1RA glucagon-like peptide-1 receptor
agonist, HbA1c glycated hemoglobin, N/A not applicable,
SD standard deviation
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individuals in this audit (baseline BMI * 40 kg/
m2 vs. 36 kg/m2 in phase 3 studies), requiring
absolute weight loss beyond that observed in
clinical trials [2, 22], particularly as these
patients may represent a more treatment-
resistant population. Therefore, the composite
endpoint of C1% HbA1c reduction coupled with
any weight loss may provide a better indication
of incretin-based therapy efficacy in this setting.
This endpoint was achieved by 60%, 48%, and
14% of patients treated with liraglutide (both
1.2 mg and 1.8 mg), exenatide, or a DPP-4i,
respectively. Of note, no records of treatment
discontinuation were identified as a
consequence of NICE recommendations. Thus,
although therapy may be initiated broadly in
keeping with current NICE guidance, there
appears to be poor adherence to therapy
discontinuation rules in routine primary care.
Patients previously receiving exenatide
achieved a 0.8% HbA1c reduction from
baseline when switched to liraglutide, in
excess of the 0.32% reduction from baseline
seen in the clinical trial switching exenatide to
liraglutide [23]. However, this may reflect
suboptimal previous exenatide therapy, as the
majority of these patients (62.6%) discontinued
exenatide due to tolerability issues. Patients
previously receiving DPP-4is demonstrated
meaningful reductions in HbA1c and body
weight from baseline when switched to
exenatide or liraglutide. This likely reflects the
higher GLP-1 receptor stimulation provided by
GLP-1RA therapy compared with DPP-4is, and
emphasizes the success of switching patients
from a DPP-4i to a GLP-1RA [24, 25].
Despite widespread use of concomitant SU
therapy, symptomatic hypoglycemia was
reported by few patients (\1%). This may
reflect underreporting by both patients and
healthcare professionals and may also be
related to the high baseline levels of glucose
control. Gastrointestinal side effects were the
most frequently reported AE in exenatide-
(33.1%) and liraglutide-treated (26.5%)
patients, in line with rates from clinical trials
[22, 26]. However, therapy discontinuation due
to gastrointestinal side effects was greater than
seen in clinical trials [6–8, 15], possibly
reflecting the impact of routine practice, as
opposed to the clinical trial setting, which often
includes highly motivated patients who
undergo more monitoring than patients in
routine clinical practice.
The health economic observations represent
the cost-effectiveness profile of liraglutide,
exenatide, and DPP-4is as prescribed in routine
clinical practice, and thus may be more
noteworthy than similar data derived from trials.
However, as this analysis was limited to within-
treatment group assessments compared with
baseline, and as patients who were prescribed
GLP-1RAs were markedly phenotypically
different from those prescribed DPP-4is, it is
impossible to directly compare the cost-
effectiveness profiles of the different therapies.
The majority of patients surveyed preferred
the GLP-1RA profile (62.5%) over the DPP-4i
profile (37.5%); however, the phenotypic profile
of the survey population may have been a
source of potential bias with respect to the
observed results. These data are at variance with
a previous study [21], and may partly reflect the
different patient populations included in each
analysis; under a third of patients included in
the previous survey had an HbA1c above their
individual target at their last doctor’s visit.
Weight loss was the most common reason for
patients choosing the GLP-1RA profile, while
mode of administration was important for those
choosing the DPP-4i profile. These observations
imply that, for patients with more advanced
disease and higher baseline body weight,
potential clinical effects, particularly relating
Diabetes Ther (2013) 4:27–40 37
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to weight loss, may outweigh barriers presented
by an injectable mode of administration. This is
supported by treatment satisfaction data from
the liraglutide versus sitagliptin phase 3 study
[11]. For patients already close to their
individual glycemic target, and for whom
weight is not a particular concern, the ease of
adding an orally administered DPP-4i to
existing therapy may, however, be preferable.
While real-world observations such as these
provide useful insight into the utility of different
therapies in clinical practice, several limitations
of the analysis should be considered. Selection
bias, the uncontrolled nature of treatment
changes, and the absence of strict research
protocols and rigorous data capture are some of
the inherent limitations. Additionally, the
patient preference analysis did not include
any validated measure of baseline health-
utility state, representing another possibly
confounding variable. Finally, for the economic
analysis, the acquisition cost of sitagliptin was
used for all patients prescribed a DPP-4i, which
might affect interpretation of these data since
there are small retail acquisition cost differences
between the prescribed DPP-4is [20].
CONCLUSION
In summary, in this retrospective analysis of
the clinical and cost-effectiveness of incretin-
based therapies initiated according to NICE
recommendations, liraglutide provided
numerically greater reductions in HbA1c and
body weight, compared with exenatide or DPP-
4is, while liraglutide, exenatide, and DPP-4is
appeared to represent cost-effective treatment
options as prescribed. Patients with more
advanced disease (higher baseline HbA1c and
longer diabetes duration) and higher baseline
BMIs appeared to prefer a drug with a GLP-1RA
profile versus a DPP-4i. The observations
from our analysis demonstrate the utility of
liraglutide in routine clinical practice and
suggest that clinical trial data appears to
translate into therapeutic benefits in routine
practice. Further research is, however, required
in both clinical trials and routine practice, to
evaluate the optimal positioning of the various
incretin-based therapies in the T2DM treatment
continuum.
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